Clinical trial
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00683722 is registered in ClinicalTrials.gov with Mesoblast, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Mesoblast, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 20, 2008
- Completion date
- August 24, 2010
- Enrollment
- 62 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
chronic bronchitis, pulmonary disease, chronic obstructive, pulmonary emphysema